Note: Claims are shown in the official language in which they were submitted.
The embodiments of the invention in which an exclusive property or privilege
is
claimed are defined as follows:
1. A device for evaluation of hemostasis, comprising:
a housing,
a plurality of test chambers each configured to receive a test sample of
blood, each
test chamber comprising a reagent or combination of reagents, wherein the
plurality of test
chambers includes at least a first test chamber and a second test chamber that
are each at
least partially defined by the housing, wherein the reagent or combination of
reagents are
mixed before testing is initiated and the mixing is accomplished outside the
respective test
chamber in a portion of the housing;
wherein the first chamber of the plurality comprises a first reagent or a
combination
of reagents that interact with the test sample of blood,
wherein the second chamber of the plurality comprises a second reagent or
combination of reagents that interact with the test sample of blood; and
wherein the first and second chambers are configured to be interrogated to
determine
a hemostatic parameter of the test samples that are received therein, wherein
the first reagent
or combination of reagents in the first test chamber is different than the
second reagent or
combination of reagents in the second test chamber; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which the test sample is introduced into the device, wherein
at least one
channel of the plurality of channels is in communication with the inlet and
with the first test
chamber and the second test chamber to deliver a portion of the test sample to
each of the
first test chamber and the second test chamber, wherein the fluid pathway
includes a first
port, defined at least in part by the housing, in communication with a channel
of the plurality
of channels and from which a pressure gradient when applied from a source
external to the
first port draws the test sample through the fluid pathway and into at least
one of the test
chambers, wherein the at least one channel of the fluid pathway includes an
inlet channel, a
27
first channel, and a second channel, wherein the inlet channel is in
communication with the
inlet, wherein the first channel is in communication with the inlet channel
and at least with
the first test chamber, and wherein the second channel is in communication
with the inlet
channel and at least with the second test chamber,
wherein at least a portion of the housing is thermally conductive to allow the
test
sample to be heated;
wherein the first reagent or combination of reagents activates the test sample
via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
wherein the second reagent or combination of reagents activates the test
sample via
an intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
at least one of the first reagent or combination of reagents and the second
reagent or
combination of reagents activates the test sample via the extrinsic pathway of
coagulation,
wherein the second reagent or combination of reagents further includes one or
both
of abciximab and cytochalasin D;
wherein the device can be used with an interrogation device to measure at
least one
viscoelastic property of the test sample.
2. The device of claim 1, further comprising:
a third chamber comprising a third reagent or combination of reagents that
interact
with the test sample of blood;
a fourth chamber comprising a fourth reagent or combination of reagents that
interact
with the test sample of blood; and
wherein the third and fourth chambers are configured to be interrogated to
determine
a hemostatic parameter of the test samples.
3. The device of claim 1 or 2, wherein the second reagent or combination of
reagents
includes abciximab.
28
4. The device of any one of claims 1 to 3, wherein the reagent or
combination of reagents
of the respective test chamber comprise kaolin, celite, glass, abciximab,
cytochalasin D,
thrombin, recombinant tissue factor, ADP, arachidonic acid, reptilase, or any
combination
thereof.
5. The device of claim 3, wherein the reagent or combination of reagents of
the respective
test chamber are lyophilized prior to interacting with the test samples.
6. The device of any one of claims 1 to 5, wherein the second reagent or
combination of
reagents includes cytochalasin D.
7. The device of claim 6, wherein the device is configured for use with a
single test sample.
8. The device of any one of claims 1 to 7, wherein the first test chamber and
the second test
chamber are designed to be interrogated to measure clot stiffness, and a
platelet index can be
determined from a differential between the clot stiffness measurement in the
first test
chamber and the clot stiffness measurement in the second test chamber.
9. The device of claim 8, wherein the housing defines at least a portion of
at least one test
chamber and of the fluid pathway, and wherein at least a portion of the
housing is thermally
conductive and is designed to be held against the heater external to the
device.
10. The device of claim 9, wherein the thermally conductive portion of the
housing defines
at least a portion of the fluid pathway.
11. The device of claim 10, wherein the thermally conductive portion comprises
a thermally
conductive polymer.
12. The device of claim 11, wherein the thermally conductive polymer is E1201.
13. The device of any one of claims 8 to 12, wherein one or more channels of
the plurality of
channels are in communication with at least one test chamber, and wherein
sample delivered
29
from the channel into the test chamber results in further mixing of at least a
portion of the
sample and the respective reagent within the respective test chamber.
14. The device of any one of claims 8 to 13, wherein a given channel of the
plurality of
channels opens into the at least one test chamber on the side and at a tangent
to the at least
one test chamber.
15. The device of any one of claims 8 to 14, further comprising a pump in
communication
with the fluid pathway.
16. The device of claim 15, further comprising a pressure transducer in
communication with
the pump to measure gauge pressure of the pump when the pump is activated.
17. The device of claim 16, further comprising a valve operable to block flow
from the pump
to allow the gauge pressure of the pump to build when the pump is activated.
18. The device of claim 17, wherein the valve is openable to expose the gauge
pressure to
the fluid pathway.
19. The device of claim 15, further comprising a pressure activated membrane
in
communication with the fluid pathway and pump, wherein the membrane is
configured to
rupture at a predetermined gauge pressure produced by the pump when the pump
is
activated.
20. The device of claim 15, further comprising a valve configured to open at a
predetermined
gauge pressure produced by the pump when the pump is activated.
21. The device of any one of claims 1 to 20, wherein one or more test chambers
of the
plurality of test chambers further comprise a magnetic stirring structure.
22. The device of any one of claims 1 to 21, wherein a portion of at least one
test chamber,
or the fluid pathway, that is in contact with the test sample is coated with
one or more
surface proteins.
23. The device of claim 23, wherein the surface proteins comprise collagen,
von Willebrand
factor (vWF), fibronectin, fibrinogen, or thrombin.
24. A method for evaluation of hemostasis in a subject, comprising:
providing a cartridge comprising a housing, a plurality of test chambers, and
a fluid
pathway, wherein the plurality of test chambers includes at least a first test
chamber and a
second test chamber that are each at least partially defined by the housing,
wherein the fluid
pathway includes an inlet, defined at least in part by the housing, through
which a test
sample is introduced into the cartridge, wherein at least one channel of the
plurality of
channels is in communication with the inlet and with the first test chamber
and the second
test chamber to deliver a portion of the test sample to each of the first test
chamber and the
second test chamber, wherein the fluid pathway includes a first port, defined
at least in part
by the housing, in communication with a channel of the plurality of channels
and from
which a pressure gradient when applied from a source external to the first
port draws the test
sample through the fluid pathway and into at least one of the test chambers;
introducing blood from the subject, through fluid pathways of the cartridge,
into the
plurality of test chambers by application of the pressure gradient from an
analysis system;
mixing a reagent or reagents with a respective test sample outside the
plurality of test
chambers in a portion of the housing before testing is initiated;
interrogating the mixed blood and reagent in the respective test chamber to
determine
a hemostatic parameter of the test samples, wherein the first and second
chambers are
configured to be interrogated to determine a given hemostatic parameter of the
test samples
that are received therein, wherein a first reagent or combination of reagents
in the first test
chamber is different than a second reagent or combination of reagents in the
second test
chamber,
31
wherein the first reagent or a combination of reagents activates the test
sample via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
wherein the second reagent or combination of reagents activates the test
sample via
an intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
at least one of the first reagent or combination of reagents and the second
reagent or
combination of reagents activates the test sample via the extrinsic pathway of
coagulation,
wherein the second reagent or combination of reagents further includes one or
both
of abciximab and cytochalasin D, wherein the interrogation comprises
measurement of at
least one viscoelastic property of the test sample.
25. The method of claim 24, wherein the given hemostatic parameter comprises
clot
stiffness.
26. The method of claim 24 or 25, wherein the given hemostatic parameter
comprises TC1,
TC2, clot stiffness, clot formation rate (CFR), TL1 or TL2.
27. The method of any one of claims 24 to 26, further comprising determining a
coagulation
factors index.
28. The method of claim 27, wherein the coagulation factors index is an
intrinsic pathway
coagulation factors index.
29. The method of claim 27, wherein the coagulation factors index is an
extrinsic pathway
coagulation factors index.
32
30. The method of any one of claims 24 to 29, further comprising determining
the intrinsic
pathway coagulation factors index, the extrinsic pathway coagulation factors
index, a
platelets index, a fibrinogen index, and a fibrinolysis index.
31. The method of any one of claims 24 to 30, wherein the reagent or reagents
are
lyophilized prior to mixing with the blood.
32. A device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at least a
first test chamber and a second test chamber that are each at least partially
defined by the
housing, wherein the first test chamber and the second test chamber are each
designed to be
interrogated to determine a hemostatic parameter of a test sample of blood
that is received
therein, wherein a first reagent or combination of reagents associated with
the first test
chamber is different than a second reagent or combination of reagents
associated with the
second test chamber; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which the test sample is introduced into the device, wherein
at least one
channel of the plurality of channels is in communication with the inlet and
with the first test
chamber and the second test chamber to deliver a portion of the test sample to
each of the
first test chamber and the second test chamber, and wherein the fluid pathway
includes a first
port, defined at least in part by the housing, in communication with a channel
of the fluid
pathway and from which a pressure gradient when applied from a source external
to the first
port draws the test sample through the at least one channel of the fluid
pathway and into at
least one of the test chambers, wherein the at least one channel of the fluid
pathway includes
an inlet channel, a first channel, and a second channel, wherein the inlet
channel is in
communication with the inlet, wherein the first channel is in communication
with the inlet
33
channel and at least with the first test chamber, and wherein the second
channel is in
communication with the inlet channel and at least with the second test
chamber,
wherein the housing includes a thermally conductive wall configured to allow
the test
sample to be heated, the thermally conductive wall having an outer surface
area and an inner
surface area;
wherein the fluid pathway includes a portion at least partially defined by the
inner
surface area of the thermally conductive wall and the outer surface area of
the thermally
conductive wall is shaped to be held in at least partially conforming contact
with or in close
proximity to a heater external to the device to allow adjustment of a
temperature of the test
sample flowing through the portion at least partially defined by the inner
surface area of the
thermally conductive wall; and
wherein the device can be used with an interrogation device to measure at
least one
viscoelastic property of the test sample.
33. The device of claim 32, wherein the device is designed to allow the test
sample to reach
about 37 C in the first test chamber and the second test chamber.
34. The device of claim 33, wherein the portion at least partially defined by
the inner surface
area of the thermally conductive wall comprises a thermally conductive polymer
that has a
thermal conductivity that exceeds 0.123 W/m K.
35. The device of any one of claims 31 to 34, further comprising a second
port, defined at
least in part by the housing, and from which a pressure gradient when applied
from a source
external to the second port causes the test sample to move from an external
vessel through
the inlet and the at least one channel of the fluid pathway and into the
housing.
36. The device of claim 35, wherein the device is designed such that a vacuum
can be
applied at the second port to introduce the test sample into the inlet and
propel the sample
into the at least one channel of the fluid pathway.
34
37. The device of claim 36, wherein the inlet is designed such that the
external vessel can
couple to establish fluid communication to allow the inlet to receive the test
sample.
38. The device of claim 37, wherein the device is designed to prevent the test
sample from
leaving through the first port or the second port.
39. The device of claim 38, wherein the fluid pathway can be coupled with a
sample
container to allow a portion of the test sample to be collected in the sample
container after it
has moved through the housing.
40. The device of any one of claims 35 to 39, wherein the first port is
configured, when
applied with the pressure gradient, to draw the test sample from the external
vessel through
the inlet and the at least one channel of the fluid pathway and into the
housing.
41. The device of any one of claims 31 to 40, wherein the device is designed
to prevent the
test sample from leaving through the first port.
42. The device of any one of claims 31 to 41, wherein the housing is designed
to allow a
fluid level to be monitored optically.
43. The device of any one of claims 31 to 42, further comprising a magnetic
stirrer.
44. The device of any one of claims 31 43, wherein the first test chamber
includes the first
reagent or combination of reagents and the second test chamber includes the
second reagent
or combination of reagents prior to receiving the test sample of blood
therein.
45. The device of claim 44, wherein one or more of the reagents are
lyophilized.
Date Recue/Date Received 2021-06-17
46. The device of any one of claims 31 to 45, wherein the housing is
configured for single
use as part of a disposable cartridge.
47. The device of any one of claims 31 to 46, wherein one or more of the
reagents are
lyophilized as lyophilized beads.
48. The device of any one of claims 31 to 47, further comprising a third test
chamber
designed to be interrogated to determine a hemostatic parameter of a third
test sample of
blood that is received therein and a third reagent or combination of reagents,
wherein the
third reagent or combination of reagents activates the third test sample via
an intrinsic
pathway of coagulation, an extrinsic pathway of coagulation, or a combination
thereof.
49. The device of claim 48, further comprising a fourth test chamber designed
to be
interrogated to determine a hemostatic parameter of a fourth test sample of
blood that is
received therein and a fourth reagent or combination of reagents, wherein the
fourth reagent
or combination of reagents activates the fourth test sample via an intrinsic
pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
50. The device of any one of claims 31 to 49, wherein the device is designed
to evaluate at
least one component of hemostasis selected from the group consisting of
initial or final fibrin
formation, fibrin or platelet activity, rate of fibrin polymerization, and
clot dissolving
process.
51. The device of any one of claims 31 to 50, wherein the device is designed
to evaluate at
least one parameter selected from the group consisting of an intrinsic pathway
coagulation
factors index, an extrinsic pathway coagulation factors index, a platelet
index, a fibrinogen
index, and a fibrinolysis index.
36
Date Recue/Date Received 2021-06-17
52. The device of claim 51, wherein the first test chamber and the second test
chamber are
designed to be interrogated to measure clot stiffness, and a platelet index
can be determined
from the differential between the clot stiffness measurement in the first test
chamber and the
clot stiffness measurement in the second test chamber.
53. The device of claim 51, wherein the device is designed to evaluate a
fibrinolysis index.
54. A device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at least a
first test chamber and a second test chamber that are each at least partially
defined by the
housing, wherein the first test chamber and the second test chamber are each
designed to be
interrogated to determine a hemostatic parameter of a test sample of blood
that is received
therein, wherein a first reagent or combination of reagents associated with
the first test
chamber is different than a second reagent or combination of reagents
associated with the
second test chamber; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which the test sample is introduced into the device, wherein
at least one
channel of the plurality of channels is in communication with the inlet and
with the first test
chamber and the second test chamber to deliver a portion of the test sample to
each of the
first test chamber and the second test chamber, and wherein the fluid pathway
includes a first
port, defined at least in part by the housing, in communication with a channel
of the fluid
pathway and from which a pressure gradient when applied from a source external
to the first
port draws the test sample through the fluid pathway and into at least one of
the test
chambers, wherein the at least one channel of the fluid pathway includes an
inlet channel, a
first channel, and a second channel, wherein the inlet channel is in
communication with the
inlet, wherein the first channel is in communication with the inlet channel
and at least with
37
Date Recue/Date Received 2021-06-17
the first test chamber, and wherein the second channel is in communication
with the inlet
channel and at least with the second test chamber,
wherein at least a portion of the housing is thermally conductive to allow the
test
sample to be heated,
wherein the first reagent or combination of reagents activates the test sample
via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof,
wherein the second reagent or combination of reagents activates the test
sample via
an intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof,
wherein at least one of the first reagent or combination of reagents and the
second
reagent or combination of reagents activates the test sample via the extrinsic
pathway of
coagulation,
wherein the second reagent or combination of reagents further includes one or
both
of abciximab and cytochalasin D, and
wherein the device can be used with an interrogation device to measure at
least one
viscoelastic property of the test sample.
55. The device of claim 54, further comprising a third test chamber designed
to be
interrogated to determine a hemostatic parameter of a third test sample of
blood that is
received therein and a third reagent or combination of reagents, wherein the
third reagent or
combination of reagents activates the third test sample via an intrinsic
pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
56. The device of claim 55, further comprising a fourth test chamber designed
to be
interrogated to determine a hemostatic parameter of a fourth test sample of
blood that is
received therein and a fourth reagent or combination of reagents, wherein the
fourth reagent
or combination of reagents activates the fourth test sample via an intrinsic
pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
38
Date Recue/Date Received 2021-06-17
57. The device of claim 56, wherein the at least one channel includes the
inlet channel, the
first channel, the second channel, a third channel, and a fourth channel,
wherein the third channel is in communication with the inlet channel and at
least with
the third test chamber, and
wherein the fourth channel is in communication with the inlet channel and at
least
with the fourth test chamber.
58. The device of any one of claims 54 to 57, wherein the device is designed
to evaluate at
least one component of hemostasis selected from the group consisting of
initial or final fibrin
formation, fibrin or platelet activity, rate of fibrin polymerization, and
clot dissolving
process.
59. The device of any one of claims 54 to 58, wherein the device is designed
to evaluate at
least one parameter selected from the group consisting of an intrinsic pathway
coagulation
factors index, an extrinsic pathway coagulation factors index, a platelet
index, a fibrinogen
index, and a fibrinolysis index.
60. The device of claim 59, wherein the first test chamber and the second test
chamber are
designed to be interrogated to measure clot stiffness, and a platelet index
can be determined
from a differential between the clot stiffness measurement in the first test
chamber and the
clot stiffness measurement in the second test chamber.
61. The device of claim 59, wherein the device is designed to evaluate a
fibrinolysis index.
62. The device of any one of claims 54 to 61,
wherein the housing includes a thermally conductive wall configured to allow
the test
sample to be heated, the thermally conductive wall having an outer surface
area and an inner
surface area,
39
Date Recue/Date Received 2021-06-17
wherein the fluid pathway includes a portion at least partially defined by the
inner
surface area of the thermally conductive wall and the outer surface area of
the thermally
conductive wall is shaped to be held in at least partially conforming contact
with or in close
proximity to a heater to allow adjustment of a temperature of the test sample
flowing through
the portion at least partially defined by the inner surface area of the
thermally conductive
wall, and
wherein the portion at least partially defined by the outer surface area of
the
thermally conductive wall is designed to be held against a heater external to
the device.
63. The device of claim 62, wherein the device is designed to allow the test
sample to reach
about 37 C in the first test chamber and the second test chamber.
64. The device of claim 63, wherein the portion at least partially defined by
the inner surface
area of the thermally conductive wall comprises a thermally conductive polymer
that has a
thermal conductivity that exceeds 0.123 W/m K.
65. The device of any one of claims 54 to 64, further comprising a second
port, defined at
least in part by the housing, and from which a pressure gradient when applied
from a source
external to the second port causes the test sample to move from an external
vessel through
the inlet and the at least one channel of the fluid pathway and into the
housing.
66. The device of claim 65, wherein the device is designed such that a vacuum
can be
applied at the second port to introduce the test sample into the inlet and
propel the sample
into the at least one channel of the fluid pathway.
67. The device of claim 66, wherein the inlet is designed such that the
external vessel can
couple to establish fluid communication to allow the inlet to receive the test
sample.
Date Recue/Date Received 2021-06-17
68. The device of claim 67, wherein the device is designed to prevent the test
sample from
leaving through the first port or the second port.
69. The device of claim 68, wherein the fluid pathway can be coupled with a
sample
container to allow a portion of the test sample to be collected in the sample
container after it
has moved through the housing.
70. The device of any one of claims 65 to 69, wherein the first port is
configured, when
applied with the pressure gradient, to draw the test sample from the external
vessel through
the inlet and the at least one channel of the fluid pathway and into the
housing.
71. The device of any one of claims 54 to 70, wherein the device is designed
to prevent the
test sample from leaving through the first port.
72. The device of any one of claims 54 to 71, wherein the housing is designed
to allow a
fluid level to be monitored optically.
73. The device of any one of claims 54 to 72, further comprising a magnetic
stirrer.
74. The device of any one of claims 54 to 73, wherein one or more of the
reagents are
lyophilized as lyophilized beads.
75. The device of any one of claims 54 to 74, wherein the housing is
configured for single
use as part of a disposable cartridge.
76. A device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at least a
first test chamber, a second test chamber, and a third test chamber that are
each at least
41
Date Recue/Date Received 2021-06-17
partially defined by the housing, wherein each of the first test chamber, the
second test
chamber, and the third test chamber are designed to be interrogated to
determine a
hemostatic parameter of a respective test sample of blood that is received
therein, wherein a
first reagent or combination of reagents, a second reagent or combination of
reagents, and a
third reagent or combination of reagents, each activates the respective test
sample via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof, and wherein the first reagent or combination of reagents is different
than the second
reagent or combination of reagents; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing,
wherein the fluid pathway includes an inlet, defined at least in part by the
housing,
through which the test sample is introduced into the device, wherein at least
one channel of
the plurality of channels is in communication with the inlet and with the
first test chamber,
the second test chamber, and the third test chamber to deliver a portion of
the test sample to
each of the first test chamber, the second test chamber, and the third test
chamber, wherein
the fluid pathway includes a first port, defined at least in part by the
housing, in
communication with a channel of the fluid pathway and from which a pressure
gradient
when applied from a source external to the first port draws the test sample
through the fluid
pathway and into at least one of the test chambers, wherein the at least one
channel of the
fluid pathway includes an inlet channel, a first channel, and a second
channel, wherein the
inlet channel is in communication with the inlet, wherein the first channel is
in
communication with the inlet channel and at least with the first test chamber,
and wherein
the second channel is in communication with the inlet channel and at least
with the second
test chamber,
wherein the fluid pathway includes a second port, defined at least in part by
the
housing, in communication with a channel of the fluid pathway and from which a
pressure
gradient when applied from a source external to the second port draws the test
sample to
move from an external vessel through the inlet and the at least one channel of
the fluid
pathway into the housing, and
42
Date Recue/Date Received 2021-06-17
wherein the fluid pathway includes a portion designed to be held against a
heater to
allow adjustment of a temperature of the test sample flowing through the
portion,
wherein the first port and/or the second port prevents the test sample from
leaving the
device,
wherein at least a portion of the housing is designed to be thermally
conductive to
allow the test sample to reach about 37 C in the test chambers; and
wherein the device is configured for use with an interrogation device to
measure at
least one viscoelastic property of the test sample.
77. A system for evaluation of hemostasis, the system comprising:
a consumable cartridge configured to be positioned in an analysis system, the
consumable cartridge comprising
a cartridge housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at
least a first test chamber and a second test chamber that are each at least
partially defined by
the cartridge housing, wherein the first test chamber and the second test
chamber are each
designed to be interrogated to determine a hemostatic parameter of a test
sample of blood
that is received therein, wherein a first reagent or combination of reagents
associated with
the first test chamber is different than a second reagent or combination of
reagents associated
with the second test chamber; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by the cartridge housing, wherein the fluid pathway includes an inlet,
defined at least in
part by the cartridge housing, through which the test sample is introduced
into the
consumable cartridge, wherein at least one channel of the plurality of
channels is in
communication with the inlet and with the first test chamber and the second
test chamber to
deliver a portion of the test sample to each of the first test chamber and the
second test
chamber, and wherein the fluid pathway includes a first port, defined at least
in part by the
cartridge housing, in communication with a channel of the fluid pathway and
from which a
pressure gradient when applied from a source external to the first port draws
the test sample
43
Date Recue/Date Received 2021-06-17
through the at least one channel of the fluid pathway and into at least one of
the test
chambers, and
a heat exchanger, and a temperature control coupled thereto, designed to allow
the
temperature of the test sample to be adjusted before analysis in the test
chambers;
an interrogation device designed to measure at least one viscoelastic property
of the
test sample;
a pressure control designed to apply the pressure gradient that causes the
test sample
to flow through the fluid pathway and into the test chambers; and
an analysis system, the analysis system comprising:
an analysis system housing having a pocket designed to receive the
consumable cartridge, the pocket comprising an actuator system that allows the
heat
exchanger, the interrogation device, and the pressure control to be positioned
adjacent to the
consumable cartridge.
78. The system of claim 77,
wherein the cartridge housing includes a thermally conductive wall configured
to
allow the test sample to be heated, the thermally conductive wall having an
outer surface
area and an inner surface area,
wherein the fluid pathway includes a portion at least partially defined by the
inner
surface area of the thermally conductive wall and the outer surface area of
the thermally
conductive wall is shaped to be held in at least partially conforming contact
with or in close
proximity to a heater external to the device to allow adjustment of a
temperature of the test
sample flowing through the portion at least partially defined by the inner
surface area of the
thermally conductive wall, and
wherein the portion at least partially defined by the outer surface area of
the
thermally conductive wall is designed to be held against the heater.
79. The system of claim 78, wherein the system is designed to allow the test
sample to reach
about 37 C in the first test chamber and the second test chamber.
44
Date Recue/Date Received 2021-06-17
80. The system of claim 79, wherein the portion at least partially defined by
the inner surface
area of the thermally conductive wall comprises a thermally conductive polymer
that has a
thermal conductivity that exceeds 0.123 W/m K.
81. The system of any one of claims 77 to 80, further comprising a second
port, defined at
least in part by the housing, and from which a second pressure gradient when
applied from a
source external to the second port causes the test sample to move from an
external vessel
through the inlet and the at least one channel of the fluid pathway and into
the cartridge
housing.
82. The system of claim 81, wherein the system is designed such that a vacuum
can be
applied at the second port to introduce the test sample into the inlet and
propel the sample
into the at least one channel of the fluid pathway.
83. The system of claim 82, wherein the inlet is designed such that the
external vessel can
couple to establish fluid communication to allow the inlet to receive the test
sample.
84. The system of claim 82, wherein the fluid pathway can be coupled with a
sample
container to allow a portion of the test sample to be collected in the sample
container after it
has moved through the cartridge housing.
85. The system of any one of claims 81 to 84, wherein the first port is
configured, when
applied with the pressure gradient, to draw the test sample from the external
vessel through
the inlet and the at least one channel of the fluid pathway and into the
cartridge housing.
86. The system of any one of claims 77 to 85, wherein the device is designed
to prevent the
test sample from leaving through the first port.
Date Recue/Date Received 2021-06-17
87. The system of any one of claims 77 to 86, wherein the cartridge housing is
designed to
allow a fluid level to be monitored optically.
88. The system of any one of claims 77 to 87, further comprising a magnetic
stirrer.
89. The system of any one of claims 77 to 88, further comprising a third test
chamber
designed to be interrogated to determine a hemostatic parameter of a test
sample of blood
that is received therein and a third reagent or combination of reagents,
wherein the third
reagent or combination of reagents activates the test sample via an intrinsic
pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
90. The system of claim 89, further comprising a fourth test chamber designed
to be
interrogated to determine a hemostatic parameter of a test sample of blood
that is received
therein and a fourth reagent or combination of reagents, wherein the fourth
reagent or
combination of reagents activates the test sample via an intrinsic pathway of
coagulation, an
extrinsic pathway of coagulation, or a combination thereof
91. The system of any one of claims 77 to 90, wherein the consumable cartridge
is designed
to evaluate at least one component of hemostasis comprising initial or final
fibrin formation,
fibrin or platelet activity, rate of fibrin polymerization, or clot dissolving
process.
92. The system of any one of claims 77 to 91, wherein the consumable cartridge
is designed
to evaluate at least one parameter comprising an intrinsic pathway coagulation
factors index,
an extrinsic pathway coagulation factors index, a platelet index, a fibrinogen
index, or a
fibrinolysis index.
93. The system of claim 92, wherein the first test chamber and the second test
chamber are
designed to be interrogated to measure clot stiffness, and a platelet index
can be determined
46
Date Recue/Date Received 2021-06-17
from the differential between the clot stiffness measurement in the first test
chamber and the
clot stiffness measurement in the second test chamber.
94. The system of claim 9692 wherein the consumable cartridge is designed to
evaluate a
fibrinolysis index.
95. The device of claim 77, wherein one or more of the reagents are
lyophilized.
96. The system of any one of claims 77 to 95, wherein the cartridge housing is
configured
for single use as part of a disposable cartridge.
97. The device of any one of claims 77 to 96, wherein the at least one channel
of the fluid
pathway includes an inlet channel, a first channel, and a second channel,
wherein the inlet channel is in communication with the inlet,
wherein the first channel is in communication with the inlet channel and at
least with
the first test chamber, and
wherein the second channel is in communication with the inlet channel and at
least
with the second test chamber.
98. The system of claim 97, wherein one or more of the reagents are
lyophilized as
lyophilized beads.
99. An apparatus for evaluation of hemostasis, comprising:
a housing;
a plurality of test chambers, including a first test chamber, a second test
chamber, and
a third test chamber, that are each at least partially defined by the housing;
and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined in part by
the housing, and
from which an external vessel establishes fluid communication, to receive a
test sample,
47
Date Recue/Date Received 2021-06-17
wherein the fluid pathway is in fluid communication with the first test
chamber, the second
test chamber, and the third test chamber to deliver the test sample, or a
portion thereof, to the
first test chamber, the second test chamber, and the third test chamber,
wherein the fluid
pathway includes a first port, defined at least in part by the housing, in
communication with
a channel of the plurality of channels and from which a pressure gradient when
applied from
a source external to the first port draws the test sample through the fluid
pathway and into at
least one of the test chambers, wherein the at least one channel of the fluid
pathway includes
an inlet channel, a first channel, a second channel, a third channel, wherein
the inlet channel
is in communication with the inlet, wherein the first channel is in
communication with the
inlet channel and at least with the first test chamber, wherein the second
channel is in
communication with the inlet channel and at least with the second test
chamber, and wherein
the third channel is in communication with the inlet channel and at least with
the third test
chamber,
wherein the housing is configured to couple to a system comprising one or more
transducers that interfaces to a respective test chamber, wherein each
respective test chamber
is configured to be interrogated by the respective one or more transducers of
the system to
determine at least one viscoelastic property of the test sample;
wherein each of the plurality of test chambers comprises a reagent or
combination of
reagents, and wherein each of the plurality of test chambers, including the
first, second, and
third test chambers, is configured to receive, via the fluid pathway, blood of
a test sample to
be interrogated to determine a plurality of hemostatic parameters;
wherein the first test chamber is associated with a first reagent or a first
combination
of reagents that interact with the blood of the respective test sample
received therein,
wherein the first reagent, or a reagent included in the first combination of
reagents, is
configured to activate coagulation via extrinsic or intrinsic pathway;
wherein the second test chamber is associated with a second combination of
reagents
that interact with blood of the respective test sample received therein,
wherein the second
combination of reagents includes i) a reagent, or a combination of reagents,
configured to
48
Date Recue/Date Received 2021-06-17
activate coagulation via the extrinsic or intrinsic pathway and ii) a reagent,
or a combination
of reagents, configured to inhibit platelet contraction; and
wherein the third test chamber is associated with a third reagent or a third
combination of reagents that interact with the blood of the respective test
sample received
therein, wherein the third reagent, or a reagent included in the third
combination of reagents,
is configured to activate coagulation via the extrinsic or intrinsic pathway.
100. The apparatus of claim 99, wherein the interrogation to determine the
hemostatic
parameter of the blood is based on a change in clot mechanical properties.
101. The apparatus of any one of claims 99 to 100, further comprising a lens
assembly that is
sealed over each of the plurality of test chambers.
102. The apparatus of claim 99, wherein the apparatus comprises a cartridge,
wherein the
cartridge defines at least a portion of the fluid pathway, and wherein at
least a portion of the
cartridge is thermally conductive.
103. The apparatus of claim 102, wherein the thermally conductive portion of
the cartridge
defines at least a portion of the fluid pathway.
104. The apparatus of claim 102, wherein the thermally conductive portion
comprises a
thermally conductive polymer.
105. The apparatus of claim 99, further comprising one or more sound focusing
apparatus
positioned to focus sound into one or more test chamber.
106. The apparatus of claim 105, wherein the sound focusing apparatus
comprises a rigid
substrate permeable by sound and an elastomeric couplant permeable by sound,
the
49
Date Recue/Date Received 2021-06-17
elastomeric couplant permeable being positioned relative to the rigid
substrate to form an
interface between the elastomeric couplant and the rigid substrate.
107. The apparatus of claim 105, wherein the sound focusing apparatus is a
sound reflector.
108. The apparatus of any one of claims 99 to 107, wherein the first reagent
or the first
combination of reagents includes a reagent selected from the group consisting
of kaolin,
celite, glass, thrombin, ellagic acid, tissue factor, and a combination
thereof, and wherein the
second combination of reagents includes a reagent selected from the group
consisting of
kaolin, celite, glass, thrombin, ellagic acid, tissue factor, abciximab,
cytochalasin D, and a
combination thereof.
109. The apparatus of claim 108, wherein the second combination of reagents
includes a first
group comprising kaolin, celite, glass, thrombin, ellagic acid, tissue factor,
or any
combination thereof, and a second group comprising abciximab, cytochalasin D,
or a
combination thereof.
110. The apparatus of any one of claims 99 to 109, wherein the evaluation of
hemostasis
comprises an assessment of components of hemostasis that include combined
effects of
coagulation, platelets, and fibrinolysis.
111. The apparatus of any one of claims 99 to 110, wherein the evaluation of
hemostasis
comprises an assessment of components of hemostasis that include plasma
coagulation
factors, platelets, fibrinogen, and fibrinolytic factors of the plasma.
112. The apparatus of any one of claims 99 to 111, wherein the first test
chamber is
configured to be interrogated by a first transducer, of the one or more
transducers, that
comprises a light emitting diode (LED) emitter and a second transducer of the
one or more
transducers comprises a detector.
Date Recue/Date Received 2021-06-17
113. The apparatus of any one of claims 99 to 112, wherein at least three
measurements are
performed in parallel within the plurality of test chambers using a
combination of agonists
and antagonists of hemostasis in at least one of the three test chambers.
114. The apparatus of any one of claims 99 to 113, wherein the apparatus is
configured to
mix the first reagent or the first combination of reagents with the test
sample in a portion of
the fluid pathway prior to being delivered to the first test chamber.
115. The apparatus of any one of claims 99 to 114, wherein the plurality of
test chambers are
configured to be interrogated by the respective transducer to provide
viscoelastic properties
of the test samples within the plurality of test chambers based on induced
displacement of
the test sample produced by the one or more transducers.
116. A system for evaluation of hemostasis comprising:
a cartridge comprising a cartridge housing, a plurality of test chambers, and
a fluid
pathway, wherein the plurality of test chambers include at least a first test
chamber and a
second test chamber that are each at least partially defined by the housing,
wherein the fluid
pathway includes an inlet, defined at least in part by the cartridge housing,
through which a
test sample is introduced into the cartridge, wherein at least one channel of
the plurality of
channels is in communication with the inlet and with the first test chamber
and the second
test chamber to deliver a portion of the test sample to each of the first test
chamber and the
second test chamber, wherein the fluid pathway includes a first port, defined
at least in part
by the cartridge housing, in communication with a channel of the plurality of
channels and
from which a pressure gradient when applied from the system to the first port
draws the test
sample through the fluid pathway and into at least one of the test chambers,
including a first
test chamber and a second test chamber, wherein each of the plurality of test
chambers is
configured to receive a reagent or combination of reagents mixed with the
respective portion
51
Date Recue/Date Received 2021-06-17
of the test sample to be interrogated to determine a hemostatic parameter of
the blood
received therein;
a system housing comprising a pocket configured to receive and securely hold
the
cartridge;
a pressure source configured to couple to the first port to the apply the
pressure
gradient to the first port;
one or more transducers for transmitting energy into one or more test chamber
of the
plurality of test chambers and for receiving reflected energy from the one or
more chambers
and the respective sample therein;
at least one processor in communication with the one or more transducers,
wherein
the processor is configured to determine the hemostatic parameters from
signals transmitted
to the processor from the one or more transducers; and
a memory having instructions stored thereon, wherein the instructions when
executed
by the at least one processor, cause the at least one processor to perform at
least three
measurements in parallel;
wherein the first test chamber comprises a first reagent or a first
combination of
reagents that interact with the blood of the test sample received therein,
wherein the first
reagent, or at least one reagent included in the first combination of
reagents, is an activator
of coagulation; and
wherein the second test chamber comprises a second combination of reagents
that
interact with blood of the test sample received therein, the second
combination of reagents
including an activator of coagulation and a reagent, or a combination of
reagents, configured
to cause a reduction in measurable changes in clot mechanical properties of
the test sample
when the test sample is interrogated by the one or more transducers.
117. The system of claim 116, wherein the clot mechanical properties comprises
one or more
viscoelastic properties of the test sample.
52
Date Recue/Date Received 2021-06-17
118. The system of claim 116 or 117, wherein the memory further comprises
additional
instructions stored thereon, wherein the additional instructions when executed
by the at least
one processor, cause the at least one processor to:
determine a curve associated with a viscoelastic property of the blood of each
test
sample, the curve being generated from the interrogation as a function of
time.
119. The system of any one of claims 116 to 118, wherein at least one of the
hemostasis
parameters is selected from the group consisting of TC1, TC2, clot stiffness,
clot formation
rate (CFR), TL1, TL2, baseline viscosity, and post lysis viscosity.
120. The system of any one of claims 116 to 119, wherein the memory further
comprises
additional instructions stored thereon, wherein the additional instructions
when executed by
the at least one processor, cause the at least one processor to determine at
least one
parameter selected from the group consisting of an intrinsic pathway
coagulation factors
index, an extrinsic pathway coagulation factors index, a platelets index, a
fibrinogen index,
and a fibrinolysis index.
121. The system of any one of claims 116 to 120, wherein the first reagent or
the first
combination of reagents are mixed with the respective test sample in a part of
a fluid
pathway prior to being delivered to the first test chamber.
122. The system of any one of claims 116 to 121, wherein the cartridge is
preloaded with
reagents for use as a single use disposable cartridge.
123. The system of any one of claims 116 to 122, further comprising
determining a plurality
of hemostatic parameters, wherein the hemostatic parameter and the plurality
of hemostatic
parameters collectively provide an assessment of main components of
hemostasis.
53
Date Recue/Date Received 2021-06-17
124. The system of any one of claims 116 to 123, wherein the transducers for
transmitting
and receiving reflected energy are configured to perform thromboelastography
(TEG) or
rotational thromboelastometry (ROTEM) techniques.
125. The system of any one of claims 116 to 124, wherein the plurality of test
chambers
comprises a material containing polystyrene.
126. The system of any one of claims 116 to 125,
wherein the first reagent or the first combination of reagents includes a
reagent
selected from the group consisting of kaolin, celite, glass, thrombin, ellagic
acid, tissue
factor, and a combination thereof,
wherein the second combination of reagents includes a reagent selected from
the
group consisting of kaolin, celite, glass, thrombin, ellagic acid, abciximab,
cytochalasin D,
tissue factor, and a combination thereof.
127. The system of claim 126, wherein the second combination of reagents
includes a first
group comprising kaolin, celite, glass, thrombin, ellagic acid, tissue factor,
or any
combination thereof, and a second group comprising abciximab, cytochalasin D,
or a
combination thereof.
128. The system of any one of claims 116 to 127, wherein the system is capable
of assessing
components of hemostasis that include plasma coagulation factors, platelets,
fibrinogen, and
fibrinolytic factors of the plasma.
129. The system of any one of claims 116 to 128, wherein a first transducer of
the one or
more transducers comprises a light emitting diode LED emitter and a second
transducer of
the one or more transducers comprises a detector.
54
Date Recue/Date Received 2021-06-17
130. The system of any one of claims 116 to 129, wherein the system is capable
of assessing
components of hemostasis that include combined effects of coagulation,
platelets, and
fibrinolysis.
131. The system of any one of claims 116 to 130, wherein the memory further
comprises
additional instructions stored thereon, wherein the additional instructions
when executed by
the at least one processor, cause the at least one processor to determine the
hemostatic
parameters based on signals transmitted to the processor, wherein the signals
are generated
from induced displacement of the test sample produced by the one or more
transducers.
132. The system of any one of claims 116 to 131, wherein the cartridge is
configured to hold
the first reagent or the first combination of reagents and the second
combination of reagents
as lyophilized beads.
133. The system of any one of claims 121 to 132, wherein the fluid pathway has
an inlet for
receiving a test sample, and wherein the fluid pathway is in fluid
communication with at
least one test chamber to deliver the test sample, or a portion thereof, to
the one or more of
the test chambers.
134. The system of claim 133, wherein at least a portion of the cartridge
comprises a
thermally conductive material.
135. The system of claim 134, wherein the portion of the cartridge defines at
least a portion
of the fluid pathway.
136. The system of claim 135, wherein the thermally conductive material
comprises a
thermally conductive polymer that has a thermal conductivity higher than
Styron 666.
137. A system for evaluation of hemostasis comprising:
Date Recue/Date Received 2021-06-17
a cartridge comprising a cartridge housing, a plurality of test chambers, and
a fluid
pathway, wherein the plurality of test chambers include at least a first test
chamber and a
second test chamber that are each at least partially defined by the housing,
wherein the fluid
pathway includes an inlet, defined at least in part by the cartridge housing,
through which a
test sample is introduced into the cartridge, wherein at least one channel of
the plurality of
channels is in communication with the inlet and with the first test chamber
and the second
test chamber to deliver a portion of the test sample to each of the first test
chamber and the
second test chamber, wherein the fluid pathway includes a first port, defined
at least in part
by the cartridge housing, in communication with a channel of the plurality of
channels and
from which a pressure gradient when applied from the system to the first port
draws the test
sample through the fluid pathway and into at least one of the test chambers,
including a first
test chamber and a second test chamber, wherein each of the plurality of test
chambers is
configured to receive a reagent or a combination of reagents mixed with the
respective
portion of the test sample to be interrogated to determine a hemostatic
parameter of the
blood received therein;
a system housing comprising a pocket configured to receive and securely hold
the
cartridge;
a pressure source configured to couple to the first port to the apply the
pressure
gradient to the first port;
one or more transducers for transmitting energy into one or more test chamber
and
for receiving reflected energy from the chamber and the sample therein;
at least one processor in communication with the one or more transducers, the
processor being configured to determine the hemostatic parameters from signals
transmitted
to the processor from the one or more transducers; and
a memory having instructions stored thereon, wherein execution of the
instructions
by the at least one processor cause the at least one processor to determine
the hemostatic
parameters in parallel;
wherein the first chamber is associated with a first reagent or a first
combination of
reagents that interact with the blood of the respective test sample received
therein, wherein
56
Date Recue/Date Received 2021-06-17
the first reagent, or a reagent included in the first combination of reagents,
is an activator of
coagulation; and
wherein the second chamber is associated with a second combination of reagents
that
interact with blood of the respective test sample received therein, the second
combination of
reagents including an activator of coagulation and a reagent, or a combination
of reagents,
configured to inhibit platelet functions.
138. The system of claim 137, wherein the memory further comprises additional
instructions
stored thereon, wherein execution of the additional instructions by the at
least one processor,
cause the at least one processor to determine a coagulation factors index.
139. The system of claim 137 or 138, wherein the memory further comprises
additional
instructions stored thereon, wherein execution of the additional instructions
by the at least
one processor, cause the at least one processor to determine at least one
parameter selected
from the group consisting of an intrinsic pathway coagulation factors index,
an extrinsic
pathway coagulation factors index, a platelets index, a fibrinogen index, and
a fibrinolysis
index.
140. The system of any one of claims 137 to 139, wherein the cartridge is
configured to hold
the first reagent or the first combination of reagents and the second
combination of reagents
as lyophilized beads.
141. The system of any one of claims 137 to 140, comprising a fluid pathway
having an inlet
for receiving the test sample, wherein the fluid pathway is in fluid
communication with at
least one of the plurality of test chambers to deliver the test sample, or a
portion thereof, to
one or more of the plurality of test chambers.
142. The system of claim 141, wherein at least a portion of the fluid pathway
comprises a
thermally conductive material.
57
Date Recue/Date Received 2021-06-17
143. The system of claim 141 or 142, wherein the fluid pathway and the
plurality of test
chambers form a portion of a cartridge, wherein a portion of the cartridge is
thermally
conductive.
144. The system of claim 143, wherein the thermally conductive portion
comprises a
thermally conductive polymer having a thermal conductivity higher than Styron
666.
145. The system of claim 141, wherein the system is configured to mix the
respective test
sample with the respective reagent or the combination of reagents prior to the
test sample
being delivered into the respective test chamber.
146. The system of any one of claims 138 to 145, wherein the one or more
transducers for
transmitting and receiving reflected energy are each configured to perform
thromboelastography (TEG) and rotational thromboelastometry (ROTEM)
techniques.
147. The system of any one of claims 138 to 145, wherein the one or more
transducers for
transmitting and receiving reflected energy are each configured to perform
sonorheometric
technique.
148. The system of claim 147, wherein the one or more transducers are each
configured to
contact an elastomeric couplant associated with a respective test chamber,
wherein each respective
elastomeric couplant is permeable by sound and is a part of a sound focusing
assembly.
149. The system of any one of claims 138 to 148,
wherein the first reagent or the first combination of reagents includes a
reagent
selected from the group consisting of kaolin, celite, glass, thrombin, ellagic
acid, tissue
factor, and a combination thereof, and
58
Date Recue/Date Received 2021-06-17
wherein the second combination of reagents include a reagent selected from the
group consisting of kaolin, celite, glass, thrombin, abciximab, cytochalasin
D, ADP,
arachidonic acid, reptilase, ellagic acid, tissue factor, and a combination
thereof
150. The system of claim 149, wherein the second combination of reagents
include a first
group comprising kaolin, celite, glass, thrombin, ellagic acid, tissue factor,
or any
combination thereof, and a second group comprising abciximab, cytochalasin D,
or a
combination thereof.
151. The system of any one of claims 138 to 150, wherein the system is capable
of assessing
components of hemostasis that include plasma coagulation factors, platelets,
fibrinogen, and
fibrinolytic factors of the plasma.
152. The system of any one of claims 138 to 151, wherein a first transducer of
the one or
more transducers comprises one or more light emitting diode LED emitter and a
second
transducer of the one or more transducers comprises a detector.
153. The system of any one of claims 138 to 152, wherein the system is capable
of assessing
components of hemostasis that include combined effects of coagulation,
platelets, and
fibrinolysis.
154. The system of any one of claims 138 to 153, wherein the memory further
comprises
additional instructions stored thereon, wherein execution of the additional
instructions by the
at least one processor cause the at least one processor to determine the
hemostatic
parameters based on signals transmitted to the processor, wherein the signals
are generated
from induced displacement of the test sample produced by the one or more
transducers.
155. An apparatus configured as a disposable cartridge, the apparatus
comprising:
a housing;
59
Date Recue/Date Received 2021-06-17
a plurality of test chambers located in the housing, the plurality of test
chambers
including chambers configured for viscoelastic measurements via a system that
interrogates
one or more viscoelastic properties of test samples in the test chambers,
wherein the one or
more viscoelastic properties is used to characterize dynamics of coagulation
and/or
fibrinolysis including clot stiffness of a clot formed in the test samples,
wherein the plurality
of test chambers comprise a first test chamber and a second test chamber each
defined by a
space sufficient to allow induced displacement of the test sample in the test
chamber from an
application of a force applied to the test sample when the system interrogates
the one or
more viscoelastic properties of the test sample; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which a blood sample is introduced into the apparatus,
wherein at least one
channel of the fluid pathway is in communication with the inlet and with the
first test
chamber and a second test chamber to deliver a portion of the blood sample to
each of the
first test chamber and the second test chamber, wherein the at least one
channel of the fluid
pathway includes an inlet channel, a first channel, and a second channel,
wherein the inlet
channel is in communication with the inlet, and wherein the first channel is
in
communication with the inlet channel and at least with the first test chamber,
and wherein
the second channel is in communication with the inlet channel and at least
with the second
test chamber, wherein the fluid pathway includes a first port, defined at
least in part by the
housing, in communication with a channel of the plurality of channels and from
which a
pressure gradient when applied from a source external to the first port draws
the test sample
through the fluid pathway and into at least one of the test chambers;
a first reagent or a first combination of reagents configured to activate
coagulation,
wherein the first reagent or the first combination of reagents is preloaded in
a first space
associated with the first test chamber for a single use in the disposable
cartridge, and
wherein the first reagent or the first combination of reagents interacts with
a portion of the
blood sample drawn through the first channel to form a first test sample,
wherein the first
test sample can be interrogated in the first test chamber to provide a first
viscoelastic
Date Recue/Date Received 2021-06-17
measurement that provides a determination of one or more clot stiffness values
of a first clot
formed in the first test sample in which the first clot is formed without
platelet aggregation
being inhibited; and
a second combination of reagents comprising i) a reagent, or a combination of
reagents, configured to activate coagulation and ii) a reagent, or a
combination of reagents,
to inhibit platelet aggregation, wherein the second combination of reagents is
preloaded in a
second space associated with the second test chamber for a single use in the
disposable
cartridge, and wherein the second combination of reagents interacts with a
portion of the
blood sample drawn through the second channel to form a second test sample,
wherein the
second test sample can be interrogated in the second test chamber to provide a
second
viscoelastic measurement that provides a determination of one or more clot
stiffness values
of a second clot formed in the second test sample in which the second clot is
formed with
platelet aggregation being inhibited, wherein the second reagent or the second
combination
of reagents comprises abciximab.
156. A system comprising the apparatus of claim 163, wherein the system
comprises:
one or more transducers;
at least one processor; and
a memory having instructions stored thereon, wherein the instructions when
executed
by the at least one processor of the system cause the at least one processor
to direct the one
or more transducers in the interrogation of the first and second test samples
to determine at
least one viscoelastic property of the first clot and the second clot,
including the one or more
clot stiffness values.
157. The system of claim 156, wherein the instructions when executed by the at
least one
processor cause the at least one processor to direct the one or more
transducers to deform the
test sample in the interrogation of the one or more viscoelastic properties.
61
Date Recue/Date Received 2021-06-17
158. The system of claim 157, wherein the system further comprises: a heater
configured to
heat the apparatus.
159. The system of claim 158, wherein the instructions when executed by the at
least one
processor further cause the at least one processor to determine platelet
function based on a
difference in response of the first viscoelastic measurement and the second
viscoelastic
measurement.
160. The system of claim 158, wherein the instructions when executed by the at
least one
processor further cause the at least one processor to determine a curve
associated with the
one or more determined clot stiffness values of the first test sample, the
curve being
generated from the interrogation as a function of time.
161. The system of claim 160, wherein the instructions when executed by the at
least one
processor further cause the at least one processor to determine a parameter
corresponding to
a reduction in viscoelastic properties indicative of fibrinolysis processes to
characterize
dynamics of fibrinolysis.
162. The system of claim 160, wherein the instructions when executed by the at
least one
processor of the system cause the at least one processor to quantify functions
of platelets,
fibrinogen, plasma factors, and fibrinolytic proteins based on the one or more
viscoelastic
properties of the test samples.
163. The system of claim 160, further comprising a display, wherein the system
is
configured, via the display, to output measurement results associated with the
one or more
clot stiffness values.
164. The apparatus of claim 156, wherein the one or more transducers comprise
at least one
ultrasonic transducer configured to generate an acoustic radiation force to
cause deformation
62
Date Recue/Date Received 2021-06-17
of the test sample, and wherein the interrogation comprises use of the
acoustic radiation
force.
165. The system of claim 155, wherein the housing comprises an outer surface
having a
shape that allows the outer surface to be held in at least partial contact
with or in close
proximity to one or more transducers, wherein the outer surface of the housing
defines a
portion of an exterior surface of each of the plurality of test chambers,
wherein the one or
more transducers are configured to deform the test sample in the interrogation
of the one or
more viscoelastic properties, and wherein each of the plurality of test
chambers has an inner
surface that extends away from the respective exterior surface of the test
chamber, to form
the space for interrogation of the one or more viscoelastic properties.
166. The apparatus of claim 155, wherein the first test chamber includes the
first reagent or
the first combination of reagents prior to receiving the test sample of blood
therein, and
wherein the second test chamber includes the second combination of reagents
prior to
receiving the test sample of blood therein.
167. The apparatus of claim 155, wherein the first reagent or a reagent of the
first
combination of reagents and/or a reagent of the second combination of
reagents, is
configured to activate coagulation comprises an extrinsic pathway activator.
168. A device configured as a disposable cartridge, the device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers include
at least a
first test chamber and a second test chamber that are each at least partially
defined by the
housing, wherein the first test chamber and the second test chamber are each
designed to
receive a test sample of blood and a reagent or combination of reagents,
wherein a first
reagent or combination of reagents in the first test chamber is different than
a second reagent
or combination of reagents in the second test chamber; and
63
Date Recue/Date Received 2021-06-17
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which the test sample is introduced into the device, wherein
at least one
channel of the plurality of channels is in communication with the inlet and
with the first test
chamber and the second test chamber to deliver a portion of the test sample to
each of the
first test chamber and the second test chamber, and wherein the fluid pathway
includes an
element having a surface defined at least in part by the housing, wherein the
element is in
communication with a channel of the fluid pathway and from which a pressure
gradient
when applied from a source external to the device draws the test sample
through the fluid
pathway and into at least one of the test chambers, wherein the at least one
channel of the
fluid pathway includes an inlet channel, a first channel, and a second
channel, wherein the
inlet channel is in communication with the inlet, and wherein the first
channel is in
communication with the inlet channel and at least with the first test chamber,
wherein the
second channel is in communication with the inlet channel and at least with
the second test
chamber;
wherein the housing includes a thermally conductive wall configured to allow
the test
sample to be heated, the thermally conductive wall having an outer surface
area and an inner
surface area, wherein the fluid pathway includes a portion at least partially
defined by the
inner surface area of the thermally conductive wall and the outer surface area
of the
thermally conductive wall is shaped to be held in at least partially
conforming contact with
or in close proximity to a heater to allow adjustment of a temperature of the
test sample
flowing through the portion at least partially defined by the inner surface
area of the
thermally conductive wall;
wherein the first reagent or combination of reagents activates the test sample
via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
wherein the second reagent or combination of reagents activates the test
sample via
an intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof;
64
Date Recue/Date Received 2021-06-17
wherein at least one of the first reagent or combination of reagents and the
second
reagent or combination of reagents activates the sample via the extrinsic
pathway of
coagulation;
wherein the second reagent or combination of reagents further includes an
antagonist
of fibrinolytic function;
wherein the first reagent or combination of reagents and the second reagent or
combination of reagents are preloaded for a single use in the disposable
cartridge;
wherein the first reagent or combination of reagents interacts with the test
sample to
be interrogated in the first test chamber to provide a viscoelastic
measurement for a
determination of one or more clot stiffness values of a clot formed in the
first test chamber;
and
wherein the second reagent or combination of reagents interacts with the test
sample
to be interrogated in the second test chamber to provide a viscoelastic
measurement for a
determination of one or more clot stiffness values of a clot formed in the
second test
chamber.
169. The device of claim 168, further comprising a third test chamber designed
to receive a
third reagent or combination of reagents, wherein the third reagent or
combination of
reagents is different from the reagents in the first test chamber and the
second test chamber,
and wherein the third reagent or combination of reagents activates the test
sample via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof.
170. The device of claim 168, wherein the device is designed, to operate with
an analysis
system, to evaluate at least one parameter selected from the group consisting
of an intrinsic
pathway coagulation factors index, an extrinsic pathway coagulation factors
index, a platelet
index, a fibrinogen index, and a fibrinolysis index.
Date Recue/Date Received 2021-06-17
171. The device of claim 168, wherein the first reagent or combination of
reagents or ii) the
second reagent or combination of reagents further includes one or both of
abciximab and
cytochalasin D.
172. The device of claim 168, wherein at least one of the plurality of test
chambers includes
a reagent or combination of reagents that allows for measurement of a
hemostatic parameter
based on a change in a mechanical property of a blood sample.
173. A device configured as a disposable cartridge, the device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at least a
first test chamber and a second test chamber that are each at least partially
defined by the
housing, wherein the first test chamber and the second test chamber are each
designed to
receive a portion of a test sample of blood and a reagent or combination of
reagents, wherein
a first reagent or combination of reagents in the first test chamber is
different than a second
reagent or combination of reagents in the second test chamber; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing, wherein the fluid pathway includes an inlet, defined at least in
part by the
housing, through which the test sample is introduced into the device, wherein
at least one
channel of the plurality of channels is in communication with the inlet and
with the first test
chamber and the second test chamber to deliver a portion of the respective
portion of the test
sample to each of the first test chamber and the second test chamber, wherein
the fluid
pathway includes an element having a surface defined at least in part by the
housing,
wherein the element is in communication with a channel of the fluid pathway
and from
which a pressure gradient when applied from a source external to the device
draws the test
sample through the fluid pathway and respectively into at least one of the
test chambers,
wherein the at least one channel of the fluid pathway includes an inlet
channel, a first
channel, and a second channel, wherein the inlet channel is in communication
with the inlet,
and wherein the first channel is in communication with the inlet channel and
at least with the
66
Date Recue/Date Received 2021-06-17
first test chamber, and wherein the second channel is in communication with
the inlet
channel and at least with the second test chamber;
wherein the housing includes a thermally conductive wall configured to allow
the test
sample to be heated, the thermally conductive wall having an outer surface
area and an inner
surface area;
wherein the fluid pathway includes a portion at least partially defined by the
inner
surface area of the thermally conductive wall and the outer surface area of
the thermally
conductive wall is shaped to be held in at least partially conforming contact
with or in close
proximity to a heater to allow adjustment of a temperature of the test sample
flowing through
the portion at least partially defined by the inner surface area of the
thermally conductive
wall;
wherein the first reagent or combination of reagents includes reptilase;
wherein the second reagent or combination of reagents includes one or both of
adenosine diphosphate and arachidonic acid,
wherein the first reagent or combination of reagents and the second reagent or
combination of reagents are each preloaded for a single use in the disposable
cartridge;
wherein the first reagent or combination of reagents interacts with a first
respective
portion of the test sample to be interrogated in the first test chamber that
provides a
viscoelastic measurement for a determination of one or more clot stiffness
values of a clot
formed in the first test chamber; and
wherein the second reagent or combination of reagents interacts with a second
respective portion of the test sample to be interrogated in the second test
chamber that
provides a viscoelastic measurement for a determination of one or more clot
stiffness values
of a clot formed in the second test chamber.
174. The device of claim 173, further comprising a third test chamber designed
to receive
another portion of the test sample of blood and a third reagent or combination
of reagents,
wherein the third reagent or combination of reagents activates the another
portion of the test
67
Date Recue/Date Received 2021-06-17
sample via an intrinsic pathway of coagulation.
175. The device of claim 174, wherein the third reagent or combination of
reagents that
activates the another portion of the test sample via the intrinsic pathway
comprises kaolin.
176. The device of claim 174, wherein the device is designed to evaluate a
platelet function
index.
177. The device of claim 173, wherein one or more of the first reagent or
combination of
reagents, the second reagent or combination of reagents, and the third reagent
or
combination of reagents are lyophilized.
178. A device configured as a disposable cartridge, the device comprising:
a housing;
a plurality of test chambers, wherein the plurality of test chambers includes
at least a
first test chamber, a second test chamber, and a third test chamber that are
each at least
partially defined by the housing, wherein each of the first test chamber, the
second test
chamber, and the third test chamber is designed to receive a respective
portion of a test
sample of blood and a respective reagent or combination of reagents, wherein a
first reagent
or combination of reagents, a second reagent or combination of reagents, and a
third reagent
or combination of reagents each activates the respective portion of the test
sample via an
intrinsic pathway of coagulation, an extrinsic pathway of coagulation, or a
combination
thereof, and wherein the first reagent or combination of reagents is different
than the second
reagent or combination of reagents, and wherein one of the reagent
combinations includes an
antagonist of fibrinolysis; and
a fluid pathway comprising a plurality of channels, each defined at least in
part by
the housing;
wherein the fluid pathway includes an inlet, defined at least in part by the
housing,
through which the test sample is introduced into the device, wherein at least
one channel of
68
Date Recue/Date Received 2021-06-17
the plurality of channels is in communication with the inlet and with the
first test chamber,
the second test chamber, and the third test chamber to deliver the respective
portion of the
test sample to each of the first test chamber, the second test chamber, and
the third test
chamber, wherein the fluid pathway includes a first port, defined at least in
part by the
housing, wherein the first port is in communication with a channel of the
fluid pathway and
from which a pressure gradient when applied from a source external to the
device draws the
test sample through the fluid pathway and into at least one of the test
chambers, wherein the
at least one channel of the fluid pathway includes an inlet channel, a first
channel, and a
second channel, wherein the inlet channel is in communication with the inlet,
and wherein
the first channel is in communication with the inlet channel and at least with
the first test
chamber, and wherein the second channel is in communication with the inlet
channel and at
least with the second test chamber;
wherein the fluid pathway includes a second port, defined at least in part by
the
housing, wherein the second port is in communication with the channel of the
fluid pathway
and from which a pressure gradient when applied from a source external to the
device draws
the test sample to move from an external vessel through the inlet and the at
least one channel
of the fluid pathway into the housing;
wherein the first port and/or the second port prevents the test sample from
leaving the
device;
wherein the housing includes a thermally conductive wall configured to allow
the test
sample to be heated, the thermally conductive wall having an outer surface
area and an inner
surface area;
wherein the fluid pathway includes a portion at least partially defined by the
inner
surface area of the thermally conductive wall and the outer surface area of
the thermally
conductive wall is shaped to be held in at least partially conforming contact
with or in close
proximity to a heater to allow adjustment of a temperature of the test sample
flowing through
the portion at least partially defined by the inner surface area of the
thermally conductive
wall;
69
Date Recue/Date Received 2021-06-17
wherein the first reagent or combination of reagents, the second reagent or
combination of reagents, and the third reagent or combination of reagents are
each preloaded
for a single use in the disposable cartridge; and
wherein the one of the reagent combinations that includes the antagonist of
fibrinolysis interacts with the test sample to be interrogated in one of the
plurality of test
chambers to provide a viscoelastic measurement for a determination of one or
more clot
stiffness values of a clot formed in the one of the plurality of test chambers
associated with
the one of the reagent combinations.
179. The device of claim 178, wherein the device is designed such that a
vacuum can be
applied at the second port to provide the pressure gradient to introduce the
test sample into
the inlet and direct the sample into the at least one channel of the fluid
pathway.
180. The device of claim 178, further comprising a coupling element defining
the inlet to
couple to a vacutainer or an external vessel and through which the test sample
is introduced
into the device.
181. The device of claim 180, wherein the first port is configured, when
applied with the
pressure gradient, to draw the test sample from the external vessel or the
vacutainer through
the inlet and the at least one channel of the fluid pathway and into the
housing.
182. The device of claim 178, wherein the housing is designed to allow a fluid
level to be
monitored optically.
183. The device of claim 178, wherein one of more of the first reagent or
combination of
reagents, the second reagent or combination of reagents, and third reagent or
combination of
reagents are lyophilized as lyophilized beads.
184. A method for evaluating hemostasis in a subject, comprising:
Date Recue/Date Received 2021-06-17
providing a disposable cartridge comprising a plurality of test chambers and a
fluid
pathway, wherein the fluid pathway includes an inlet for receiving a blood
sample of the
subject, wherein the inlet communicates with an inlet channel in the
cartridge, the inlet
channel communicating with at least a first channel and a second channel,
wherein the first
channel is in fluid communication with a first test chamber and the second
channel is in fluid
communication with a second test chamber, wherein the fluid pathway includes a
first port in
communication with a channel of the first channel and a second channel and
from which a
pressure gradient when applied from a source external to the first port draws
the test sample
through the fluid pathway and into at least one of the test chambers, and
wherein the
disposable cartridge includes a thermally conductive portion;
introducing the blood sample into the inlet and then the inlet channel of the
cartridge,
wherein a first portion of the blood sample is received in the first channel
and the first test
chamber and a second portion of the blood sample is received in the second
channel and the
second test chamber,
adjusting the temperature of the blood sample, or a portion thereof, along the
thermally conductive portion;
allowing the first portion of the blood sample to mix with a first reagent or
combination of reagents to produce a first test sample;
allowing the second portion of the blood sample to mix with a second reagent
or
combination of reagents to form a second test sample;
initiating displacement within the first test sample;
interrogating the first test sample in the first test chamber to measure a
first change in
mechanical properties of the first test sample;
determining, by a processor, a first curve associated with stiffness of the
first test
sample as a function of time;
determining at least one parameter including a first parameter selected from
the
group consisting of clot time, clot stiffness, clot formation rate, and lysis
time from the first
curve;
initiating displacement within the second test sample;
71
Date Recue/Date Received 2021-06-17
interrogating the second test sample in the second test chamber to measure a
second
change in mechanical properties of the second test sample;
determining, by the processor, a second curve associated with stiffness of the
first
test sample as a function of time; and
determining at least one parameter including a second parameter selected from
the
group consisting of clot time, clot stiffness, clot formation rate, and lysis
time from the
second curve;
wherein a combination of said first parameter and said second parameter
provides an
indication of a state of hemostasis in the subject; and wherein the
interrogation to determine
the first parameter and the second parameter is based on a viscoelastic
measurement of the
blood sample.
185. The method of claim 184, wherein the step of initiating displacement of
the first test
sample and the step of initiating displacement of the second test sample are
peiformed at the
same time.
186. The method of claim 184, further comprising assessing platelet function
by determining
a differential between the first parameter and the second parameter, wherein
the second
reagent or combination of reagents further includes an antagonist of platelet
aggregation.
187. The method of claim 184, wherein at least one of the first parameter and
the second
parameter is associated with the stiffness of a fibrin network formed in the
respective
sample.
188. The method of claim 184, wherein the first reagent or combination of
reagents includes
an activator of coagulation that activates the first test sample via an
intrinsic pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
72
Date Recue/Date Received 2021-06-17
189. The method of claim 188, wherein the first reagent or combination of
reagents includes
an activator of coagulation that activates the first test sample via an
intrinsic pathway of
coagulation and the second reagent or combination of reagents includes an
activator of
coagulation that activates the second test sample via an extrinsic pathway of
coagulation.
190. The method of claim 189, wherein the first parameter and the second
parameter both
include clot time.
191. The method of claim 188, further comprising: allowing a third portion of
the blood
sample to mix with a third reagent or combination of reagents to produce a
third test sample;
initiating displacement within the third test sample; and interrogating the
third test sample in
a third test chamber to measure a third change in mechanical properties of the
third test
sample and to determine at least one parameter including a third parameter
selected from the
group consisting of clot time, clot stiffness, clot formation rate, and lysis
time from said third
change in the mechanical properties.
192. The method of claim 191, wherein the third reagent or combination of
reagents includes
an activator of coagulation that activates the third test sample via an
intrinsic pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof.
193. The method of claim 191, wherein the third reagent or combination of
reagents further
includes an antagonist of fibrinolysis.
194. The method of claim 188, further comprising: evaluating, by the
processor, a derivative
of the first curve to determine the first parameter of the first test sample.
195. The method of claim 194, wherein the step of determining the first
parameter
comprises: determining, by the processor, a clot time for the first test
sample based on a
comparison of the derivative of the first curve to a threshold value.
73
Date Recue/Date Received 2021-06-17
196. The method of claim 188, wherein at least one of the first parameter and
the second
parameter is determined based on an application of the viscoelastic
measurement to a
viscoelastic model.
197. The method of claim 188, further comprising: determining an intrinsic
pathway
coagulation factors index, an extrinsic pathway coagulation factors index, a
platelets index, a
fibrinogen index, a fibrinolysis index, or a combination thereof, of the blood
sample.
198. The method of claim 188, wherein the thermally conductive portion is
located along the
fluid pathway.
199. The method of claim 198, wherein the temperature of the blood sample, or
a portion
thereof, is adjusted to a temperature at or near normal body temperature.
200. The method of claim 188, wherein the first portion is mixed with the
first reagent or
combination of reagents prior to entering the first test chamber, and allowing
the second
portion is mixed with the second reagent or combination of reagents prior to
entering the
second test chamber.
201. The method of claim 200, wherein the step of allowing the first portion
of the blood
sample to mix with the first reagent or combination of reagents to produce the
first test
sample includes providing a magnetic component in the disposable cartridge and
applying a
magnetic field to facilitate mixing of the first portion of the blood sample
and the first
reagent or combination of reagents to produce the first test sample.
202. The method of claim 188, further comprising: applying a pressure
differential from a
source external to the disposable cartridge to draw at least a portion of the
blood sample to at
least one of the first test chamber and the second test chamber.
74
Date Recue/Date Received 2021-06-17
203. The method of claim 202, wherein the step of applying the pressure
differential from
the source external to the disposable cartridge includes applying a vacuum to
the disposable
cartridge.
204. The method of claim 202, further comprising: preventing the blood sample
from
flowing out of the disposable cartridge.
205. The method of claim 188, wherein at least one of the first parameter and
the second
parameter is determined based on an elastic component derived from the
viscoelastic
measurement of the blood sample.
206. The method of claim 188, further comprising: optically monitoring a fluid
level in at
least a portion of the disposable cartridge.
207. The method of claim 188, further comprising: transmitting a first energy
into the first
test chamber; and receiving a reflected second energy therefrom, wherein the
received
reflected second energy is used to determine the first parameter.
208. The method of claim 207, wherein the first energy and the second energy
are of the
same form, and the form is acoustic energy.
209. A method for evaluating hemostasis in a subject, comprising:
feeding a blood sample of the subject to a disposable cartridge through an
inlet in the
cartridge, wherein the blood sample is directed through the inlet into an
inlet channel in the
cartridge through application of a pressure differential applied from a test
system to a port in
communication with the inlet channel to draw the blood sample through at least
the inlet
channel and into a plurality of test chambers, wherein a first portion of the
blood sample
flows from the inlet channel into a first channel and a first test chamber and
a second portion
Date Recue/Date Received 2021-06-17
of the blood sample flows into a second channel and a second test chamber, and
wherein the
disposable cartridge includes a thermally conductive portion therein;
adjusting the temperature of the blood sample, or a portion thereof, along the
thermally conductive portion;
mixing the first portion of the blood sample with a first reagent or
combination of
reagents to produce a first test sample, wherein the first reagent or
combination of reagents
includes an activator of coagulation that activates the first test sample via
an intrinsic
pathway of coagulation;
mixing the second portion of the blood sample with a second reagent or
combination
of reagents to form a second test sample, wherein the second reagent or
combination of
reagents includes an activator of coagulation that activates the second test
sample via an
extrinsic pathway of coagulation;
initiating displacement within the first test sample;
interrogating the first test sample in the first test chamber to measure a
first change in
mechanical properties of the first test sample;
determining at least one parameter including a first parameter selected from
the
group consisting of clot time, clot stiffness, clot formation rate, and lysis
time from said first
change in mechanical properties;
initiating displacement within the second test sample;
interrogating the second test sample in the second test chamber to measure a
second
change in mechanical properties of the second test sample; and
determining at least one parameter including a second parameter selected from
the
group consisting of clot time, clot stiffness, clot formation rate, and lysis
time from said
second change in mechanical properties;
wherein a combination of said first parameter and second parameter provides an
indication of a state of hemostasis in the subject; and
wherein the interrogation to determine the first parameter and/or the second
parameter is based on a viscoelastic measurement of the blood sample.
76
Date Recue/Date Received 2021-06-17
210. The method of claim 209, wherein the step of feeding the blood sample to
the
disposable cartridge comprises:
inserting the blood sample into the disposable cartridge through the inlet
from a
sample container; or drawing the blood sample into the disposable cartridge
through the inlet
from the sample container.
211. The method of claim 210, further comprising:
mixing a third portion of the blood sample with a third reagent or combination
of
reagents to produce a third test sample, wherein the third reagent or
combination of reagents
includes an activator of coagulation that activates the first test sample via
an intrinsic
pathway of coagulation or an extrinsic pathway of coagulation;
initiating displacement within the third test sample;
interrogating the third test sample in a third test chamber to measure a third
change in
mechanical properties of the third test sample, and
determining at least one parameter selected from the group consisting of clot
time,
clot stiffness, clot formation rate, and lysis time from said third change in
mechanical
properties of the third test sample, wherein said third parameter, or a
combination of the
third parameter with the first parameter and/or second parameter, provides
further indication
of the state of hemostasis in the subject.
212. The method of claim 211, further comprising assessing platelet function
by determining
a differential between i) the first parameter or the second parameter and ii)
the third
parameter, wherein the third parameter is determined based on a clot stiffness
measurement
of the third test sample, and wherein the third reagent or combination of
reagents further
includes an antagonist of platelet aggregation.
213. The method of claim 212, wherein the third parameter is associated with
the stiffness of
a fibrin network formed in the respective sample.
77
Date Recue/Date Received 2021-06-17
214. The method of claim 213, wherein the first parameter and the second
parameter both
include clot time.
215. The method of claim 211, further comprising:
mixing a third portion of blood sample with a third reagent or combination of
reagents to produce a third test sample; initiating displacement within the
third test sample;
and
interrogating the third test sample in the third test chamber to determine at
least one
parameter including a third parameter selected from the group consisting of
clot time, clot
stiffness, clot formation rate, and lysis time.
216. The method of claim 215, wherein the third reagent or combination of
reagents includes
an activator of coagulation that activates the third test sample via an
intrinsic pathway of
coagulation, an extrinsic pathway of coagulation, or a combination thereof,
and wherein the
third reagent or combination of reagents further includes an antagonist of
fibrinolysis.
217. The method of claim 209, wherein the step of determining the first
parameter or the
second parameter comprises: determining, by a processor, a curve associated
with a clot
stiffness of the respective test sample as a function of time.
218. The method of claim 217, further comprising: evaluating, by the
processor, a derivative
of the curve to determine the first parameter and/or the second parameter of
the respective
test sample.
219. The method of claim 218, further comprising: determining, by the
processor, a clot time
for the test sample based on a comparison of the derivative of the curve to a
threshold value.
78
Date Recue/Date Received 2021-06-17
220. The method of claim 209, wherein at least one of the first parameter and
the second
parameter is determined based on an application of the viscoelastic
measurement to a
viscoelastic model.
221. The method of claim 209, further comprising: determining an intrinsic
pathway
coagulation factors index, an extrinsic pathway coagulation factors index, a
platelets index, a
fibrinogen index, a fibrinolysis index, or a combination thereof, of the blood
sample.
222. A method for evaluating hemostasis of a subject, comprising:
providing a disposable cartridge comprising a plurality of test chambers and a
fluid
pathway, wherein the fluid pathway includes an inlet for receiving a blood
sample, wherein
the inlet communicates with an inlet channel in the cartridge, the inlet
channel
communicating with at least a first channel and a second channel, wherein the
first channel
is in fluid communication with a first test chamber and the second channel is
in fluid
communication with a second test chamber, wherein the fluid pathway includes a
first port in
communication with a channel of the first channel and a second channel and
from which a
pressure gradient when applied from a test system to the first port draws the
test sample
through the fluid pathway and into at least one of the test chambers, and
wherein the
disposable cartridge includes a thermally conductive portion;
introducing the blood sample into the inlet and then the inlet channel of the
cartridge,
wherein a first portion of the blood sample is received in the first channel
and the first test
chamber and a second portion of the blood sample is received in the second
channel and the
second test chamber;
adjusting the temperature of the blood sample, or a portion thereof, along the
thermally conductive portion;
applying the pressure differential from the test system to the first port of
the
disposable cartridge to draw at least a portion of the blood sample to at
least one of the first
test chamber and the second test chamber;
preventing the blood sample from flowing out of the disposable cartridge;
79
Date Recue/Date Received 2021-06-17
allowing the first portion of the blood sample to mix with a first reagent or
combination of reagents to produce a first test sample;
allowing the second portion of the blood sample to mix with a second reagent
or
combination of reagents to form a second test sample;
interrogating the first test sample in the first test chamber to determine at
least one
parameter including a first parameter selected from the group consisting of
clot time, clot
stiffness, clot formation rate, and lysis time; and
interrogating the second test sample in the second test chamber to determine
at least
one parameter including a second parameter selected from the group consisting
of clot time,
clot stiffness, clot formation rate, and lysis time;
wherein a combination of said first parameter and said second parameter
provides an
indication of a state of hemostasis in the subject; and
wherein the interrogation to determine the first parameter, the second
parameter, or a
combination thereof is based on a viscoelastic measurement of the blood
sample.
223. The method of claim 222, wherein the first portion is mixed with the
first reagent or
combination of reagents prior to entering the first test chamber, and wherein
the second
portion is mixed with the second reagent or combination of reagents prior to
entering the
second test chamber.
224. The method of claim 223, wherein the step of mixing the first portion of
the blood
sample with a first reagent or combination of reagents to produce a first test
sample includes
providing a magnetic component in the disposable cartridge and applying a
magnetic field to
facilitate mixing of the first portion of the blood sample and the first
reagent or combination
of reagents to produce the first test sample.
225. The method of claim 222, wherein the step of applying the pressure
differential from
the source external to the disposable cartridge includes applying a vacuum to
the disposable
cartridge.
Date Recue/Date Received 2021-06-17
226. The method of claim 222, wherein at least one of the first parameter and
the second
parameter is determined based on an elastic component derived from the
viscoelastic
measurement of the blood sample.
227. The method of claim 222, further comprising: optically monitoring a fluid
level in at
least a portion of the disposable cartridge.
228. The method of claim 222, further comprising: transmitting a first energy
into the first
test chamber or onto a transducer associated therewith; and receiving a
reflected second
energy therefrom, wherein the received reflected second energy is used to
determine the first
parameter.
229. A system for evaluation of hemostasis, comprising:
a cartridge comprising:
a cartridge housing, a plurality of test chambers, and a fluid pathway,
wherein
the plurality of test chambers include at least a first test chamber and a
second test
chamber that are each at least partially defined by the housing, wherein the
fluid
pathway includes an inlet, defined at least in part by the cartridge housing,
through
which a test sample is introduced into the cartridge, wherein at least one
channel of
the plurality of channels is in communication with the inlet and with the
first test
chamber and the second test chamber to deliver a portion of the test sample to
each
of the first test chamber and the second test chamber, wherein the fluid
pathway
includes a first port, defined at least in part by the cartridge housing, in
communication with a channel of the plurality of channels and from which a
pressure
gradient when applied from the system to the first port draws the test sample
through
the fluid pathway and into at least one of the test chambers;
a first chamber of the plurality comprising a first reagent or a first
combination of reagents that interact with the blood received therein, wherein
the first
81
Date Recue/Date Received 2021-06-17
reagent, or a reagent included in the first combination of reagents, is an
activator of
coagulation;
a second chamber of the plurality comprising a second combination of
reagents that interact with blood of the test sample received therein, the
second combination
including an activator of coagulation and one or both of abciximab and
cytochalasin D;
a third chamber comprising a third reagent or combination of reagents that
interact with blood of the test sample received therein;
a fourth chamber comprising a fourth reagent or combination of reagents that
interact with blood of the test sample received therein; wherein the third and
fourth
chambers are configured to be interrogated to determine a hemostatic parameter
of the test
sample.
wherein the first reagent and the second combination of reagents are
lyophilized prior to interacting with the test samples;
a system housing comprising a pocket configured to receive and securely hold
the
cartridge
a pressure source configured to couple to the first port to the apply the
pressure
gradient to the first port; and
an interrogation device that measures at least one viscoelastic property of
the test
sample.
230. The system of claim 229, wherein the interrogation device is configured
to use acoustic
radiation force.
231. The system of claim 229, wherein the interrogation device is configured
to transmit
sound into the one or more test chamber.
232. A system for evaluation of hemostasis comprising:
a plurality of test chambers each configured to receive blood of a test
sample, each
test chamber comprising a reagent or combination of reagents;
82
Date Recue/Date Received 2021-06-17
wherein a first chamber of the plurality comprises an activator of coagulation
that
interact with the blood received therein;
wherein a second chamber of the plurality comprises an activator of
coagulation and
one or both of abciximab and cytochalasin D that interact with blood of the
test sample
received therein the combination including an activator of coagulation and;
wherein the first chamber is configured to be interrogated with ultrasound for
a
hemostatic parameter of the blood received therein to be determined;
wherein the second chamber is configured to be interrogated with ultrasound
for a
hemostatic parameter of the blood received therein to be determined;
a transducer for transmitting ultrasound into one or more test chamber and for
receiving reflected ultrasound from the chamber and the sample therein;
and at least one processor in communication with the transducer, the processor
being
configured to determine the hemostatic parameters from signals transmitted to
the processor
from the transducer.
233. The system of claim 232, wherein the hemostasis parameters are selected
from the
group consisting of TC1, TC2, clot stiffness, clot formation rate (CFR), TL1,
TL2, baseline
viscosity, and post lysis viscosity.
234. The system of claim 232, wherein the processor is further configured to
determine a
coagulation factors index.
235. The system of claim 232, wherein the processor is further configured to
determine at
least one parameter selected from the group consisting of an intrinsic pathway
coagulation
factors index, an extrinsic pathway coagulation factors index, a platelets
index, a fibrinogen
index, and a fibrinolysis index.
83
Date Recue/Date Received 2021-06-17
